{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:47:24Z","timestamp":1790876844704,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:17:00Z","timestamp":1720930620000},"page":"1478-1486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study"],"prefix":"10.1016","volume":"7","author":[{"given":"Daimantas","family":"Milonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Chlosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Everaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giansilvio","family":"Marchioro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sanchez-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Van Der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.05.016_b0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.05.016_b0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","article-title":"Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial","volume":"62","author":"Mottet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0015","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.05.016_b0020","doi-asserted-by":"crossref","first-page":"163.e7","DOI":"10.1016\/j.urolonc.2014.11.018","article-title":"Natural history of surgically treated high-risk prostate cancer","volume":"33","author":"Briganti","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.05.016_b0025","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3389\/fonc.2019.01286","article-title":"Significance of time until PSA recurrence after radical prostatectomy without neo- or adjuvant treatment to clinical progression and cancer-related death in high-risk prostate cancer patients","volume":"9","author":"Venclovas","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2024.05.016_b0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2013.03.053","article-title":"Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy","volume":"65","author":"Touijer","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2015.04.035","article-title":"Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival","volume":"68","author":"Nini","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0040","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.05.016_b0045","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.05.016_b0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.05.016_b0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0060","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2018.07.027","article-title":"Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer","volume":"75","author":"Tosco","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0070","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.016_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1590\/S1677-5538.IBJU.2013.05.05","article-title":"Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy","volume":"39","author":"Harty","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1442-2042.2012.02993.x","article-title":"Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer","volume":"19","author":"Abdollah","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.016_b0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","article-title":"The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. results from the Local Treatment of Metastatic Prostate Cancer (LoMP) registry","volume":"29","author":"Lumen","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.05.016_b0095","doi-asserted-by":"crossref","unstructured":"Tsuboi I, Matsukawa A, Kardoust Parizi M, et al. A systematic review and meta-analysis of the impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.03.007.","DOI":"10.1016\/j.euo.2024.03.007"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:11:28Z","timestamp":1737832288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124001470"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.016","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}